The global CBD skincare market is booming. According to Grand View Research, the market was valued at $234.1 million in 2018, and is expected to grow at a CAGR of 32.9% from 2019 to 2025. That’s a strong catalyst for companies such as Ayurcann Holdings Corp. (CSE: AYUR)(FSE:3ZQ0), The Valens Company (TSX:VLNS)(OTC:VLNCF), Auxly Cannabis Group Inc. (OTC:CBWTF)(TSX:XLY), Tilray Inc. (NASDAQ:TLRY), Medipharm Labs Corporation (OTC:MEDIF) (TSX:LABS). In addition, Grand View Research notes, “CBD is considered safe and effective for all skin types but is particularly useful for people who struggle with sensitivity, inflammatory conditions, acne, and dryness related to skin. Owing to these strong inflammatory properties, CBD helps in the skin’s natural healing process, lowering the life span of breakouts and eczema flare-ups. CBD also showcases potential antioxidant properties that can help in counteracting signs of aging. It can even help in reducing pain caused by inflammatory skin conditions.”

Ayurcann Holdings Corp. Entering Canada’s Largest Market with Topical Skincare Line

Ayurcann Holdings Corp., a Canadian extraction company specializing in the processing of cannabis and hemp to produce oils and various derivative products, is pleased to announce the launch of their high potency THC and CBD-infused topical skincare line; GLOW. Ayurcann will launch their line of GLOW products through the Ontario Cannabis Store. Products will be made available through additional adult-use channels including the provincial retailers and storefronts across Ontario.

To start, Ayurcann will be launching GLOW’s Day cream and Night cream combo pack. The product's quick absorbing formula works fast to enhance applied to areas. Harnessing the power of the cannabis plant, GLOW’s non-psychoactive formula uses both THC and CBD blended with high-quality natural botanicals and essential oils.

The initial product launch includes two SKUs: GLOW Day Cream and GLOW Night Cream. GLOW Day Cream contains a total of 1000mg of CBD, while the Night Cream contains a mix of500mg THC and 500mg of CBD. With the introduction of one of the highest concentrations of active cannabinoids on the market in a topical format, Ayurcann’s strategy is to expand market share in extract and extract derivatives while providing exceptional products to consumers. GLOW is poised to be a top choice among consumers entering the cannabis space in search of topical products due to its premium quality and value-based price points. In a 2021 report on Canadian cannabis consumers, Deloitte noted that nearly half of new users are more likely to prefer CBD-only products with 34% of existing consumers citing general health & wellness as drivers of CBD consumption.

“We are thrilled to announce GLOW’s initial entrance into the Canadian market through the OCS, where we are optimistic about its market potential as an industry leading cannabinoid- based topical line. We have been pleasantly surprised by the initial interest from consumers and retailers for these products and believe they will help set the standard for cannabinoid-based topicals,” states Igal Sudman, CEO of Ayurcann.

The Valens Company and Citizen Stash Cannabis Corp. are pleased to announce the successful completion of the previously announced plan of arrangement, whereby Valens has acquired all of the issued and outstanding common shares and other securities of Citizen Stash in an all share transaction, effective November 8, 2021. Under the terms of the Arrangement, Citizen Stash shareholders are entitled to 0.1620 of a Valens common share for each Citizen Stash Common Share held.

Auxly Cannabis Group Inc., a leading consumer packaged goods company in the cannabis products market, is pleased to announce that, in connection with its strategic partnership with Imperial Brands PLC, the Company has appointed Murray McGowan, Chief Strategy and Development Officer for Imperial, to its Board of Directors, effective November 1, 2021. Mr. McGowan will join the Auxly Board of Directors as Imperial’s director designee, replacing previous Imperial nominee Conrad Tate. Mr. Tate has left Imperial but, at the request of the Company, has agreed to remain on Auxly’s Board as an independent director and will also continue to serve on Auxly’s Audit Committee and Compensation Committee. Mr. McGowan has also been appointed to the Company’s Audit Committee. Following the appointment of Mr. McGowan, the Board will comprise of six directors.

Tilray Inc. announced that two of its leading brands, SweetWater Brewing Company and RIFF Cannabis, have collaborated for the exclusive U.S. launch of SweetWater RIFF -- SweetWater’s first ready-to-drink (RTD) cocktail and its inaugural entry into the spirits category. SweetWater RIFF brings a unique twist on RTD vodka sodas in two offerings: SweetWater RIFF Citrus and SweetWater RIFF Strawberry Mule. “SweetWater’s entry into the spirits category reflects the essence of the SweetWater brand: original, compelling and enticing,” said Brian Miesieski, SweetWater’s Chief Marketing Officer. “SweetWater RIFF delivers a great-tasting ready-to-drink cocktail with a premium taste developed in partnership with RIFF’s own highly curated, expertly made approach. We are incredibly excited to expand and create something that is a great alternative to our incredible selection of beers and seltzers.”

Medipharm Labs Corporation a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15, 2021. Bryan Howcroft brings over 20 years of leadership in multiple industries including medical devices, healthcare imaging, and manufacturing. Most recently, Bryan held the position of Chief Operational Officer and Chief Financial Officer of Southmedic, a company that provides healthcare products, custom manufacturing, and distribution in over 60 countries globally. Bryan's previous experience makes him the ideal executive appointment in the international cannabis industry as the healthcare sector, like cannabis, is heavily regulated and requires expertise in navigating complex global regulatory regimes, including the US FDA, and country-specific medical distribution regulations. Bryan’s tenure at Southmedic included an extremely significant scaling of the business to a multisite operation. Southmedic is recognized as one of Canada's largest privately held medical device companies.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Ayurcann Holdings Corp. by Ayurcann Holdings Corp. We own ZERO shares Ayurcann Holdings Corp.